Studio di efficacia e sicurezza su satralizumab (SA237) in monoterapia per il trattamento di partecipanti con neuromielite ottica (NMO) e disturbo dello spettro della neuromielite ottica (NMOSD)

Risultati degli studi clinici

Once the last participant has completed the clinical trial, Roche will analyze the combined results of the trial and create a report summarizing the results. The analysis of the data takes time; however Roche aims to make the summary of the outcome of the clinical trial available within 12 months after the last clinical trial participant has completed the trial. Roche may also provide a summary of trial outcome prior to the end of the clinical trial. Below you can find the available results of the SAkuraStar_309 clinical trial.